Form 4: Verona Pharma CEO Sells Shares Under 10b5-1 Plan

Verona Pharma's CEO, David Zaccardelli, sold 1,600 ordinary shares at $5 each, as part of a pre-arranged trading plan.

Summary

• David Zaccardelli, the President and CEO of Verona Pharma, sold 1,600 ordinary shares on November 25, 2024, at a price of $5 per share.
• This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 8, 2024.
• Following the sale, Zaccardelli beneficially owns 15,200,752 ordinary shares, which includes shares underlying restricted share units and ADSs.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a pre-planned share sale by the CEO, which is neither positive nor negative in itself. The use of a 10b5-1 plan suggests no negative implications.

Industry Context

This is a routine disclosure of an insider transaction, which is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any recent material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a standard practice for executives at publicly traded companies to avoid accusations of insider trading.
• Many companies such as Pfizer, Moderna, and BioNTech have executives who use similar plans to manage their personal holdings.
• The volume of shares sold is relatively small compared to the total holdings of the CEO, which is not unusual for these types of transactions.

Stakeholder Impact

• The share sale is unlikely to have a significant impact on shareholders, as it was a small transaction under a pre-arranged plan.

Key Dates

Keywords

Verona Pharma, David Zaccardelli, share sale, Rule 10b5-1, insider trading, ordinary shares, ADS